Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (177)	3/27/1998 12:43:00 PM
From: Harold Engstrom	Read Replies (1) \| Respond to of 340

Teva's study is PR and not adequate for labelling changes. Teva couldn't show positive data under rigorous scientific controls so it went and bought a study that would create a marketing splash. If Copaxone can be demonstrated to show effectiveness under rigorous clinicals, then patients should consider it as a second choice to Avonex, Betaseron or Rebif. In my opinion, Teva's management is coming under some serious heat for Copaxone's flop and this is their way of meeting that pressure.